Medical Devices

New FDA-cleared Persona PLUS technology promises to increase plasma yields per donor, tackling the growing global demand for life-saving therapies.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.

The life sciences giant's significant dividend hike underscores its robust financial health and commitment to growth, even as it pursues major acquisitions.

After a major trial miss sent its stock tumbling, GRAIL will face investors to pitch its vision for the future of early cancer detection technology.

A Florida jury found Publix 100% liable for a fall that led to three spinal surgeries for a young mother, rejecting the company's $600k offer.

A new Ontario program is giving breast cancer patients access to a life-changing drug a year sooner, setting a potential new standard for Canada.

A massive new study finds ECGs save young lives, questioning UK policy as 12 die weekly from hidden heart conditions. Is repeat screening the answer?

A landmark study confirms a minimally invasive radiofrequency device is highly effective for chronic rhinitis, offering lasting relief beyond traditional sprays.

With new backing from One Six 8 Ventures, health tech firm Respiree accelerates its US and Canadian expansion of its FDA-cleared AI platform.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

Dupixent's landmark FDA approval offers a new, surgery-sparing option for a debilitating sinus disease, but questions of access and cost remain.

PGA star Max Homa shares his hidden health battle with seborrheic dermatitis, urging millions to trade self-diagnosis for a doctor's visit.

A new partnership aims to put advanced digital tools in more dentists' hands, tackling key adoption barriers with enhanced local support and integrated workflows.

A new study confirms Theranica's migraine wearable won't disrupt glucose monitors, a major breakthrough for 4.5 million Americans with both conditions.

Despite missing its primary goal, Cadrenal Therapeutics' drug CAD-1005 drastically cut deadly blood clots, setting up a crucial FDA meeting for a new path forward.

Medtronic's diabetes arm hits the road for its IPO, seeking to raise up to $784M in a major test of investor appetite for specialized medtech firms.

A new report on 1,800+ patients reveals a model for obesity care that preserves muscle, sustains weight loss, and may solve the GLP-1 cost crisis.

After a pivotal trial failure, Alector will present its new strategy at a key health conference, focusing on its innovative brain-delivery platform.

Fort Worth Plastic Surgery's new partnership with a PE-backed group highlights a major industry shift, raising questions about growth, autonomy, and patient care.

The maker of Wegovy and Ozempic announces a massive price cut. We explore what this means for patients, competitors, and the future of drug pricing.